Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled Phase II Study of Vismodegib (GDC-0449, Systemic Hedgehog Antagonist) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

NCT00636610 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00636610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00636610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled Phase II Study of Vismodegib (GDC-0449, Systemic Hedgehog Antagonist) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
December 31, 2010
Enrollment
199 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer